EUVIMEDEUVIMED entdecken
EditorialOpen Access · CC BY 4.0

JAK Inhibitors: A Double‐Edged Sword in Immune‐Mediated Diseases Management

Luisa Bertin iD, Edoardo Vincenzo Savarino

United European Gastroenterology Journal · 2025-05 · 13 (4) · 505-507

DOI: 10.1002/ueg2.12716 ↗

Kurz gefasst

Editorial in der Zeitschrift United European Gastroenterology Journal, online erschienen am 29.11.2024. Verfasst von Luisa Bertin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Unit, Azienda Ospedale Università Padova, Padova, Italy. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Inflammatory Bowel Diseases, Intestinal Perforation, Janus Kinase Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

JAK inhibitors are pivotal in treating immune‐mediated inflammatory diseases (IMIDs) like rheumatoid arthritis (RA) and inflammatory bowel disease. However, emerging safety concerns warrant careful evaluation. A recent analysis of the FDA Adverse Event Reporting System (FAERS) revealed that RA patients using JAK inhibitors face nearly double the risk of gastrointestinal perforations (GIPs) compared to those on biologics, particularly with concurrent steroid or NSAID use. Additionally, the FDA's ORAL Surveillance study linked tofacitinib with higher rates of cancer and cardiovascular events, prompting regulatory restrictions. These findings highlight the importance of balancing JAK inhibitors' therapeutic benefits with potential risks, emphasizing the need for patient‐centred risk assessment and vigilant monitoring to optimize outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidInflammatory Bowel DiseasesIntestinal PerforationJanus Kinase InhibitorsHumansAdverse Drug Reaction Reporting SystemsNeoplasmsPiperidinesPyrimidinesRisk AssessmentUnited States

Stichwörter der Autor:innen

JAK inhibitorsgastrointestinal perforationrheumatoid arthritissafety

Substanzen

Janus Kinase InhibitorsPiperidinesPyrimidinestofacitinib

Autor:innen und Institutionen

  • Gastroenterology Unit, Azienda Ospedale Università Padova, Padova, Italy.
  • Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
  • Humanitas Clinical and Research Center, IRCCS, Rozzano, Italy.

ORCID-Profile: Luisa Bertin

Zitieren

APA

Bertin, L., & Savarino, E. V. (2025). JAK Inhibitors: A Double‐Edged Sword in Immune‐Mediated Diseases Management. United European Gastroenterology Journal, 13(4), 505-507. https://doi.org/10.1002/ueg2.12716

Vancouver

Bertin L, Savarino EV. JAK Inhibitors: A Double‐Edged Sword in Immune‐Mediated Diseases Management. United European Gastroenterology Journal. 2025;13(4):505-507. doi:10.1002/ueg2.12716

BibTeX
@article{Bertin2025,
  author = {Bertin, Luisa and Savarino, Edoardo Vincenzo},
  title = {JAK Inhibitors: A Double‐Edged Sword in Immune‐Mediated Diseases Management},
  journal = {United European Gastroenterology Journal},
  year = {2025},
  volume = {13},
  number = {4},
  pages = {505--507},
  doi = {10.1002/ueg2.12716}
}
Kostenlos starten →